The Lancet. Diabetes: a defining disease of the 21st century. Lancet. 2023;401(10394):2087. https://doi.org/10.1016/s0140-6736(23)01296-5.

Article  CAS  PubMed  Google Scholar 

World Health Organization. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 27 May 2024.

Gough SC, Kragh N, Ploug UJ, Hammer M. Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England. Diabetes Metab Syndr Obes. 2009;2:179–84. https://doi.org/10.2147/dmsott.s7088.

Article  PubMed  PubMed Central  Google Scholar 

Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus—an overview. Int J Mol Sci. 2024;25(3):1882. https://doi.org/10.3390/ijms25031882.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11–20. https://doi.org/10.1016/j.cmet.2021.12.012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11(11):1185–200. https://doi.org/10.7150/ijms.10001.

Article  PubMed  PubMed Central  Google Scholar 

Tan Q, Akindehin SE, Orsso CE, Waldner RC, DiMarchi RD, Müller TD, Haqq AM. Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes. Front Endocrinol (Lausanne). 2022;13: 838410. https://doi.org/10.3389/fendo.2022.838410.

Article  PubMed  Google Scholar 

U.S. Food and Drug Administration. MOUNJARO™ (tirzepatide) injection for subcutaneous use. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf.

U.S. Food and Drug Administration. ZEPBOUND™ (tirzepatide) injection for subcutaneous use. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf.

France NL, Syed YY. Tirzepatide: a review in type 2 diabetes. Drugs. 2024;84(2):227–38. https://doi.org/10.1007/s40265-023-01992-4.

Article  CAS  PubMed  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. https://doi.org/10.1056/NEJMoa2206038.

Article  CAS  PubMed  Google Scholar 

Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–26. https://doi.org/10.1016/s0140-6736(23)01200-x.

Article  CAS  PubMed  Google Scholar 

Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909–18. https://doi.org/10.1038/s41591-023-02597-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. https://doi.org/10.1001/jama.2023.24945.

Article  CAS  PubMed  Google Scholar 

Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205–18. https://doi.org/10.1002/(sici)1520-7560(199905/06)15:3%3c205::aid-dmrr29%3e3.0.co;2-o.

Article  CAS  PubMed  Google Scholar 

Kolotkin RL, Crosby RD, Williams GR, Hartley GG, Nicol S. The relationship between health-related quality of life and weight loss. Obes Res. 2001;9(9):564–71. https://doi.org/10.1038/oby.2001.73.

Article  CAS  PubMed  Google Scholar 

Lee PG, Cigolle CT, Ha J, Min L, Murphy SL, Blaum CS, Herman WH. Physical function limitations among middle-aged and older adults with prediabetes: one exercise prescription may not fit all. Diabetes Care. 2013;36(10):3076–83. https://doi.org/10.2337/dc13-0412.

Article  PubMed  PubMed Central  Google Scholar 

Poon JL, Marshall C, Johnson C, Pegram H, Hunter M, Kan H, Ahmad N. Development of a conceptual model to present the impacts of obesity on physical functioning. J Endocr Soc. 2020;4(Suppl 1):SUN-LB102. https://doi.org/10.1210/jendso/bvaa046.2058.

Article  PubMed Central  Google Scholar 

Kolotkin RL, Andersen JR. A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life. Clin Obes. 2017;7(5):273–89. https://doi.org/10.1111/cob.12203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rozjabek H, Fastenau J, LaPrade A, Sternbach N. Adult obesity and health-related quality of life, patient activation, work productivity, and weight loss behaviors in the United States. Diabetes Metab Syndr Obes. 2020;13:2049–55. https://doi.org/10.2147/dmso.S245486.

Article  PubMed  PubMed Central  Google Scholar 

Höchsmann C, Dorling JL, Martin CK, Earnest CP, Church TS. Association between weight loss, change in physical activity, and change in quality of life following a corporately sponsored, online weight loss program. BMC Public Health. 2022;22(1):451. https://doi.org/10.1186/s12889-022-12835-4.

Article  PubMed  PubMed Central  Google Scholar 

Ul-Haq Z, Mackay DF, Fenwick E, Pell JP. Meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the SF-36. Obesity (Silver Spring, Md). 2013;21(3):E322–7. https://doi.org/10.1002/oby.20107.

Article  PubMed  Google Scholar 

Müller-Nordhorn J, Muckelbauer R, Englert H, et al. Longitudinal association between body mass index and health-related quality of life. PLoS ONE. 2014;9(3): e93071. https://doi.org/10.1371/journal.pone.0093071.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pearl RL, Wadden TA, Tronieri JS, et al. Short- and long-term changes in health-related quality of life with weight loss: results from a randomized controlled trial. Obesity (Silver Spring, Md). 2018;26(6):985–91. https://doi.org/10.1002/oby.22187.

Article  PubMed  PubMed Central  Google Scholar 

Hageman PA, Mroz JE, Yoerger MA, Pullen CH. Weight loss is associated with improved quality of life among rural women completers of a web-based lifestyle intervention. PLoS ONE. 2019;14(11): e0225446. https://doi.org/10.1371/journal.pone.0225446.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas. 2018;9:353–67. https://doi.org/10.2147/prom.S156279.

Article  PubMed  PubMed Central  Google Scholar 

Langendoen-Gort M, Groeneveld L, Prinsen CAC, et al. Patient-reported outcome measures for assessing health-related quality of life in people with type 2 diabetes: a systematic review. Rev Endocr Metab Disord. 2022;23(5):931–77. https://doi.org/10.1007/s11154-022-09734-9.

Article  PubMed  PubMed Central  Google Scholar 

Ren J, Bushmakin AG, Cislo PR, Abraham L, Cappelleri JC, Dworkin RH, Farrar JT. Meaningful within-patient change for clinical outcome assessments: model-based approach versus cumulative distribution functions. J Biopharm Stat. 2023. https://doi.org/10.1080/10543406.2023.2281575.

Article  PubMed  Google Scholar 

Maruish ME. User’s manual for the SF-36v2 health survey. 3rd ed. Lincoln: Quality Metric Incorporated; 2011.

Google Scholar 

Kolotkin RL, Williams VSL, Ervin CM, et al. Validation of a new measure of quality of life in obesity trials: impact of weight on quality of life-lite clinical trials version. Clin Obes. 2019;9(3): e12310. https://doi.org/10.1111/cob.12310.

Article  PubMed  PubMed Central